News Releases & Research Results Molecular design of Smart Nanomachine® for treating Alzheimer's dementia with a low dose of antibody drug

The results of collaborative R&D project led by the Kawasaki Institute of Industrial Promotion Innovation Center of NanoMedicine (iCONM), the Department of Bioengineering, Graduate School of Engineering, the University of Tokyo, and the Department of Neurology and Neurological Science, Tokyo Medical and Dental University.

• Brain amyloid β (Aβ) aggregation was successfully inhibited with a low dose of antibody drug in an Alzheimer-type dementia model mouse through the molecular design and synthesis of Smart Nanomachine® (*) that efficiently delivers an antibody drug to the brain.
  * Spherical or rod-shaped molecular aggregates with a size of tens of nanometers, formed through the aggregation of amphipathic polymers with various functional molecules in water.
• Specifically, Smart Nanomachine® can deliver 3D6-Fab, an antibody with inhibitory effects on Aβ aggregation, into the brain 42 times more efficiently and at a lower dose (1/10) than conventional methods.
• The results of R&D should reduce the dose of the antibody drug under development for the treatment of Alzheimer's dementia.

This R&D project was conducted with the support of the Strategic Research Program for Brain Sciences (SRPBS) by AMED.

The results of R&D were published online in the American Chemical Society (ACS) journal ACS Nano on May 21.

Jinbing Xie, et al. Dual-Sensitive Nanomicelles Enhancing Systemic Delivery of Therapeutically Active Antibodies Specifically into the Brain ACS Nano
DOI：10.1021/acsnano.9b09991